Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
Open Access
- 4 October 2004
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 4 (1) , 39
- https://doi.org/10.1186/1471-2334-4-39
Abstract
Background: A dengue virus type 2 (DEN-2 Tonga/74) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of DEN-2 viruses. To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Δ30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate. Methods: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Δ30. Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys. Neutralizing antibody induction and protective efficacy were also assessed in rhesus monkeys. Results: The rDEN2Δ30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when compared to the parent virus. The rDEN-2 viruses were not infectious for Aedes mosquitoes, but both readily infected Toxorynchites mosquitoes. In rhesus monkeys, rDEN2Δ30 appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of viremia and neutralizing antibody induction. A derivative of rDEN2Δ30, designated rDEN2Δ30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Δ30 in SCID-HuH-7 mice. Conclusions: The rDEN2Δ30 and rDEN2Δ30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.Keywords
This publication has 35 references indexed in Scilit:
- Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunityVaccine, 2004
- Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine DevelopmentJournal of Virology, 2003
- Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeysVaccine, 2003
- Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cellsVaccine, 2003
- A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in MonkeysJournal of Virology, 2003
- Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in MonkeysJournal of Virology, 2002
- Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in MiceJournal of Virology, 2001
- Differential Susceptibility ofAedes aegyptito Infection by the American and Southeast Asian Genotypes of Dengue Type 2 VirusVector-Borne and Zoonotic Diseases, 2001
- Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteersVaccine, 2001
- Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic feverThe Lancet, 1999